28 June 2021

PanCryos- a university spin-off to 'keep an eye on'

Nature outlook

Pancryos, a spinoff company from Novo Nordisk Foundation Center for Stem Cell Biology – DanStem, has been named “2021 Ones to watch” by Nature Research Awards’ Spinoff Prize.

PanCryos is a spin-off arising from the Novo Nordisk Foundation Center for Stem Cell Biology (DanStem) at the University of Copenhagen. The company is aiming to develop a next generation stem cell derived allogeneic cell therapy (PanINSULA™) for type 1 diabetes. Based on novel IP, PanCryos will – for the first time – enable the definitive safety and large scale manufacturing of insulin cells for therapeutic use. PanCryos is in the pre-clinical stage of development and is addressing cost effective scalability and manufacturing of the cell therapy early on to ensure successful commercialization.

PanCryos is founded by stem cell biologists Assistant Professor Jacqueline Ameri and Professor Henrik Semb who have assembled a team of highly experienced business advisors, regulatory consultants, islet transplantation experts and cell manufacturing CMOs with the goal of testing a mature beta cell therapy in a phase I/IIa clinical trial. 

Read more: http://pancryos.com/